MHRA approval of imlunestrant offers a new option for patients with ESR1-mutated, ER-positive advanced breast cancer.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/targeted-tablet-approved-esr1-breast-cancer-2026a10005xy?src=rss
Author :
Publish date : 2026-02-25 14:11:00
Copyright for syndicated content belongs to the linked Source.
